Program to help families manage diabetes distress in children
Official title: Remedy to Diabetes Distress (R2D2): A Scalable Screen to Treat Program for School-age Families
Run by Nemours Children's Clinic · NCT05268250 · Data updated 2026-11-12
This study is testing a new program to help families of school-age children with Type 1 Diabetes manage stress related to the condition and see if it improves their health.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 8 Years to 65 Years |
| Sex | All |
| Enrollment | 180 (estimated) |
| Sponsor | Nemours Children's Clinic Academic / other |
| Locations | 2 sites (Jacksonville, Florida and 1 other locations) |
| Status | Recruiting |
| Started | February 26, 2024 |
| Main results expected | August 31, 2027 |
| Study ends | August 31, 2027 |
| Registry record updated | September 1, 2026 |
| Trial ID | NCT05268250 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are children aged 8-12 years with a physician-confirmed diagnosis of Type 1 Diabetes who experience diabetes distress.
✕Probably not a fit
Patients who are on a conventional insulin regimen or do not report diabetes distress levels at or above clinical cut-points may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project aims to evaluate a new program called Remedy to Diabetes Distress (R2D2) designed to help families of school-age children with Type 1 Diabetes (T1D) manage diabetes distress. The program will assess the feasibility and acceptability of a mobile health intervention that targets both children and their parents, focusing on reducing diabetes distress to improve glycemic control. By addressing the emotional and psychological challenges associated with T1D, the study seeks to enhance the overall management of the condition in young patients. The initial efficacy of the R2D2 program will also be tested to determine its impact on children's health outcomes.
Why it matters
Potential benefit: If successful, this program could significantly improve the emotional well-being of families and enhance glycemic control in children with Type 1 Diabetes.
How similar studies have gone: While there is ongoing research into diabetes distress, this specific approach with a scalable program for families is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * child age between 8-12 years, physician confirmed T1D diagnosis, * either the child or the parent or both the child and parent report diabetes distress levels at or above clinical cut-points, * child is on an intensive insulin regimen (pump or MDI). Exclusion Criteria: * children on a conventional insulin regimen, children and/or parents who do not report diabetes distress levels at or above the clinical cut-points, * children who have an allergy or sensitivity to the adhesive and/or skin preparation used for CGM, children with a comorbid chronic condition (e.g., renal disease), * children and parents who do not speak English.
Where it's running
-
Nemours Children's Health
Jacksonville, Florida, United States Recruiting -
Children's Mercy Kansas City
Kansas City, Missouri, United States Recruiting
Study contacts
- Principal investigator: Susana R Patton, PhD — Nemours Children's Health
- Study coordinator: Susana R Patton, PhD
- Email: susana.patton@nemours.org
- Phone: 9046972000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Semaglutide on body composition in adults with type 1 diabetes and overweight/obesity
This study tests whether weekly semaglutide changes body composition in adults with type 1 diabetes who are overweight or obese, compared with a placebo over 24 weeks.
-
Next Generation Extended Wear Sensors in Type 1 and Type 2 Diabetes
This study tests a new extended wear sensor and algorithm in people with type 1 or type 2 diabetes to see how well it works across adults and children.
-
CGM-guided carb awareness education for adults with Type 1 diabetes
This study tests whether teaching mealtime insulin dosing using CGM data helps adults with Type 1 diabetes who don’t usually count carbs.
-
Safety and effectiveness of GLP-1 receptor agonists and SGLT inhibitors added to insulin in adults with type 1 diabetes
This registry will see if adding GLP-1RA or SGLTi therapies to insulin helps adults with type 1 diabetes over one year.
-
Think-Find-Solve activities for insulin self-management in children with type 1 diabetes
A behavior-change activity book is tested with children aged 8–12 with type 1 diabetes and their parents to see if it improves daily insulin self-management.
-
Near-sensor insulin delivery with CGM in people with type 1 diabetes
A small early-feasibility study tests a dual-port insulin patch pump that includes a CGM sensor to see if delivering insulin near the sensor affects glucose readings and whether an automated control algorithm can manage glucose.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.